JAZZ News and Press, Jazz Pharmaceuticals plc From 08/06/20

Jazz Pharmaceuticals ( JAZZ +3.3% ) is up again, albeit on below-average volume, adding to its up move after its posted better-than-expected Q2 results with more bullish guidance Tuesday after the close. Shares have rallied  14%  since then. Highlights: More news on: Jazz Pharm...

Jazz Pharmaceuticals (NASDAQ: JAZZ) hasn't given investors much good news so far in 2020. The drugmaker's first-quarter results announced in May were disappointing. Jazz stock has dropped 23% year to date.  But Jazz appears to be hitting more right notes now. The company announced it...

The following slide deck was published by Jazz Pharmaceuticals plc in conjunction with their 2020 Q2 earnings Read more ...

Jazz Pharmaceuticals plc (JAZZ) Q2 2020 Earnings Conference Call August 4, 2020 4:30 P.M. ET Company Participants Kathy Littrell - Head of Investor Relations Bruce Cozadd - Chief Executive Officer Renee Gala - Chief Financial Officer Dan Swisher - President Rob Iannone - Ex...

Jazz Pharmaceuticals (NASDAQ: JAZZ ) : Q2 Non-GAAP EPS of $3.71 beats by $0.60 ; GAAP EPS of $2.06 beats by $0.21 . Revenue of $562.4M (+5.3% Y/Y) beats by $59.21M . R&D $78.9M vs. $63.7M consensus. Press Release More news on: Jazz Pharmaceuticals plc, Earnings news and com...

DUBLIN , Aug. 4, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2020 and updated its 2020 financial guidance. "I am proud that we delivered strong financial and operational results above our expectations d...

Quick Take Harmony Biosciences Holdings ( HRMY ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement . The firm is a biopharma commercializing its WAKIX molecule for the treatment of excessive sleepiness in adult narcolepsy. HRMY has...

On Wednesday, J azz Pharmaceuticals' (NASDAQ: JAZZ) Xywav won Food and Drug Administration approval as a treatment for people with narcolepsy. The drug has been found to reduce cataplexy -- a sudden loss of muscle tone -- and excessive daytime sleepiness associated with the condition. T...

The FDA has approved Jazz Pharmaceuticals' (NASDAQ: JAZZ ) Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of cataplexy (excessive daytime sleepiness) in patients at least seven year old with narcolepsy. More news on: Jazz Pharmaceuticals plc,...

Xywav is the first FDA approved new treatment option indicated for both cataplexy and excessive daytime sleepiness in people living with narcolepsy in more than 15 years Xywav contains 92 percent less sodium per nightly dose than sodium oxybate, a current standard of care for this patie...